| http://www.w3.org/ns/prov#value | - Vioxx is an interesting case, at the time that the larger clinical trials of Vioxx (e.g. Vigor) were being undertaken the evidence that COX-2 inhibitors might cause thrombosis by suppressing the vasodilator prostacyclin and shifting the prostacyclin/thromboxane balance towards the vasoconstrictor thromboxane was quite limited, though though it got a lot stronger in the 5 years before Vioxx was fin
|
